Clinical Trial Update: Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma [NA]

View source ↗

Summary

Clinical trial update evaluating the use of the radiolabeled antibody 124I-cG250 for early detection of response to therapy in metastatic renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• 124I-cG250

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Renal Cancer | NA | Status: ACTIVE_NOT_RECRUITING